iPS cells grew out of research on returning mature cells to a pluripotent state. The iPS-derived EV discussed on this page is not an explanation of placing iPS cells themselves into the body. An EV is a small particle a cell releases. When the route is made from patient-derived personal iPS, the source, the explanation of it as single-source, the quality records, and the creation period are positioned as an area where research and commercialization are advancing, and a physician then organizes them one at a time during the consultation. We start not from the impression of a name, but from what can be confirmed.
Entry: consultation (physician review) / an explanation of the general flow and its "positioning" (kept separate from the filed plans) / confirming source, quality records, and alternatives / shared before your visit via LINE or email.
iPS-derived EV is not a matter of placing iPS cells themselves into the body; it is a consultation that confirms the source and quality records of an extracellular vesicle (EV). It is not something you receive right away — creation, storage, and quality confirmation are checked in order. Even if not every record is in hand, you can begin a records consultation by sending what you have via LINE or WhatsApp.
You do not need every record in hand. You can begin a records consultation by sending what you have via LINE or WhatsApp.
iPS-derived EV is confirmed for source and quality as an extracellular vesicle. It is not an explanation of placing iPS cells themselves into the body.
We confirm whether it can be traced as patient-derived and single-source. Anything of unknown origin or whose records cannot be confirmed is not taken as a premise.
It is not treated in the same framework as the filed provision plans. As a medical area where research and commercialization are advancing, a physician explains it individually.
We separate what is understood from what is not yet understood. No outcome is taken as a premise.
Based on the records, a physician organizes which options should be considered. The schedule (an estimate for creation and manufacture) is confirmed at the consultation.
Reading the phrase "iPS-derived EV" alone, people often take it to mean placing iPS cells themselves into the body. In reality it is a different matter. The EV (extracellular vesicle) discussed here is a small, sac-like particle released by a cell — it is not the cell itself. Rather than the impression a name gives, what to look at is which cell it derives from and which quality records can confirm it. Seeing that before you decide is the starting point.
Even when there are prominent names or papers in the research background, that alone does not determine the quality of an individual product or a medical outcome. The clinic positions this as an area where research and commercialization are advancing, and a physician explains source, quality records, alternatives, risks, costs, and follow-up individually during the consultation.
Which cell it derives from and whose cells it was made from — can this be traced? Particular caution is needed where the origin is unknown, multiple donors are involved, or quality records cannot be confirmed.
Can lot, sterility, endotoxin, mycoplasma, particle count, size distribution, purification process and similar items be confirmed through records rather than a verbal account?
Does a physician set out, within informed consent, that this differs from widely established standard care in Japan, and separate what is understood from what is not yet understood?
The phrase "iPS-derived EV" alone is not enough for a medical decision. What you want to see is source, manufacturer, lot, certificate of quality, storage and transport, the points that should be explained separately from care that is widely standardized in Japan, and the physician explanation and follow-up at our clinic.
iPS-derived EV is not an explanation of placing iPS cells themselves into the body. We confirm the source and product specifications as an extracellular vesicle.
We confirm the supporting records for product quality: lot, certificate of quality, particle count, protein amount, sterility, endotoxin, mycoplasma, and storage and transport conditions.
Within informed consent we make clear the boundary that product quality rests with the manufacturer, while medical judgment, explanation, and follow-up rest with our clinic.
EV stands for extracellular vesicle — a small, sac-like particle released by a cell. It is not the cell itself. As a particle that has left the cell, we trace its source and contents through records.
Personal iPS-derived EV is explained as a route made from the patient's own cells. Unlike products derived from multiple donors, it matters that whose cells it was made from can be traced.
Particle count gives a rough indication of amount, and size distribution shows the spread of particle sizes. Number or size alone, however, is not a basis for judging a medical outcome.
There are steps to recover EVs from the culture medium and reduce unwanted components and differently sized material. We look at which method is used to purify and which records confirm it.
Cargo means freight. If you picture an EV as a small envelope, the cargo is the information inside it — proteins, RNA, lipids, and so on. What matters is not the size of a number alone. We look separately at what may be contained, by which method it was measured, and whether it can be confirmed in records lot by lot.
A small, sac-like particle released by a cell. Not the cell itself; we look at the source and quality of it as a particle.
Research databases report many EV-related proteins, mRNA, miRNA, lipids, and more. They are sometimes described in the thousands, but that does not mean all of them are inside a single particle.
Rather than an impression that "a lot is in there," we confirm particle count, size distribution, protein amount, purification process, sterility, endotoxin, mycoplasma and similar items as records.
Reference: public databases such as ExoCarta and Vesiclepedia organize molecular information related to EVs. These help in understanding the research background; they do not indicate the quality or treatment outcome of an individual product.
Illustrative consultation image. It does not represent actual treatment content or results.
iPS-derived EV is not something to decide on by a research name or manufacturer name alone. Even where a manufacturer or research institution has records or papers, we do not treat those as the deciding factor; we organize them as confirmation records that trace source, manufacturing, lot, release decision, and storage and transport.
Rather than relying on a verbal account, we read the determination results — sterility, endotoxin, mycoplasma, particle count, size distribution, and the recovery, purification, and filtering steps — in the per-lot quality records. This is so we can explain separately what can be confirmed and what is still not yet known over the long term.
We confirm where it was made and under which lot it was shipped.
We look at when it was determined and under which conditions the record applies.
We confirm, in the records, the determination items related to contamination risk.
We look at items to confirm for culture-derived products together with temperature and transport records.
We confirm how many particles are contained and how the size range is presented.
We confirm in the records how unwanted components and differently sized material are reduced.
We confirm whether it is a route traceable as patient-derived rather than derived from multiple donors.
We explain separately the items that can be confirmed in records and the points still not yet known over the long term.
iPS-derived EV is not treated as the same as the Type-2 MSC or Type-3 NK filed provision plans. Positioning it as a medical area where research and commercialization are advancing, a physician organizes and explains individually during the consultation that it differs from widely established standard care in Japan, along with quality records, alternatives, risks, costs, and follow-up.
Without assuming it is the same framework as widely established standard care in Japan or a filed regenerative-medicine provision plan, we organize its boundary, what is understood, and what is still not yet understood.
We confirm the quality records provided by the manufacturer and explain them to the patient.
At our clinic we are responsible for physician explanation, feasibility, follow-up, and the contact arrangements in case of an adverse event.
Without presupposing a result, we explain separately what can and cannot be confirmed.
This is not something to receive right away; it is a process of creating, storing, and consulting while confirming the quality records.
See the research background and papers →
The 2012 Nobel Prize in Physiology or Medicine was awarded to Dr. John Gurdon and Professor Shinya Yamanaka for the discovery that mature cells can be returned to a pluripotent state.
iPS cells emerged from research that introduces a small number of genes into cells that already have a role in the body and returns them to a pluripotent state. This idea of "returning" is called reprogramming.
However, this page does not explain "putting in iPS cells" or "the body's state being restored." It is a page for organizing the map of how to receive an explanation of iPS-derived EV as an extracellular vesicle and which quality records to confirm.
An idea born from research that returns mature cells to a pluripotent state.
iPS-derived EV is not an explanation of placing iPS cells into the body; it is about how to confirm the small particles a cell releases.
Source, particle count, size distribution, purification, lot, and release decision are confirmed in records, separately from the name.
This is to help understanding before the consultation. Feasibility and individual judgment are confirmed by a physician with records and an examination.
Organize existing records, wishes, and medical history, and gather the points you want to confirm about personal iPS-derived EV.
A route to create and store iPS cells from the patient's own cells; the guide time is roughly six months.
Manufacturing iPS-derived EV is expected to take roughly two more months, with quality records, storage, and shipment conditions confirmed.
Feasibility, cost, risks, and unconfirmed points are explained individually with records and an examination.
This flow is for understanding before the consultation. Actual feasibility and the content of the explanation are confirmed individually.
Personal iPS is a commissioned route in which your own cells are collected from urine, skin tissue, or similar and created and stored as iPS cells. Unlike products derived from multiple donors, it can be traced as patient-derived and single-source — this becomes an important point to confirm. Creation involves steps such as infection screening, sampling, reprogramming, quality confirmation, and a certificate of storage.
As a guide, creating personal iPS takes roughly six months, and manufacturing personal iPS-derived EV from there takes roughly two more months. When iPS cells are to be created from now, expect about eight months overall, and the schedule is confirmed at the consultation.
If your own iPS cells have already been created and stored, there may be the possibility of consulting from the EV manufacturing stage. The actual feasibility, timing, cost, required documents, and quality records are confirmed individually after you make an inquiry.
It proceeds from urine or skin tissue and similar. There are items that must be confirmed before creation, such as HIV, hepatitis B, hepatitis C, and syphilis.
In creating iPS cells there is a step that changes the cell state using reprogramming factors. We also confirm in the records that it is not something that propagates as an RNA virus.
After the iPS cells are created and stored, we confirm concentration, particle count, size distribution, and the recovery and purification steps, then proceed to manufacturing iPS-derived EV.
Detailed manufacturer information, creation timing, minimum manufacturing volume, storage, shipment records, cost, and the consent form are confirmed in records after an inquiry.
A cell born from research that returns mature body cells to a pluripotent state. It forms a large background for regenerative medicine and drug discovery research.
Oct3/4, Sox2, Klf4, c-Myc and others are known as the factors used in research that rewinds the cell state.
An EV is a small particle released by a cell. iPS-derived EV is not an explanation of placing iPS cells themselves into the body; as an extracellular vesicle, we confirm its source and quality records.
A physician explains its positioning as an area where research and commercialization are advancing, along with the manufacturer, certificate of quality, storage and transport, cost, risks, alternatives, and the consent form.
No. The iPS-derived EV discussed on this page is not an explanation of placing iPS cells themselves into the body. An EV (extracellular vesicle) is a small, sac-like particle released by a cell, separate from the cell itself. We confirm its source and contents through the product specifications and quality records.
No. In the route made from patient-derived personal iPS, there are steps such as infection screening, sampling, reprogramming, quality confirmation, and a certificate of storage; when iPS cells are to be created from now, expect a corresponding period overall. The actual feasibility, timing, cost, required documents, and quality records are confirmed individually after you make an inquiry.
It is not treated as the same. Positioning it as a medical area where research and commercialization are advancing, a physician organizes and explains individually during the consultation that it differs from widely established standard care in Japan, along with quality records, alternatives, risks, costs, and follow-up.
No. Even with a research name, manufacturer name, or papers, that alone does not determine the quality of an individual product or a medical outcome. We confirm source, manufacturing, lot, sterility, endotoxin, mycoplasma, particle count, size distribution, purification process and similar items in the per-lot quality records.
Rather than the name, the quality records: source, donor, origin, contamination measures, shipment records and similar. Particular caution is needed where the origin is unknown, multiple donors are involved, or quality records cannot be confirmed; our clinic has a physician explain those whose source and quality records can be confirmed. For personal iPS-derived EV, we confirm whether it can be traced as patient-derived and single-source.
What an EV is, and the points to confirm for source, origin, and quality records.
The current state of particle count, size, cargo, iPSC-derived MSC-EV, and the intranasal route and CNS research.
Confirm MSC quality, how suitability is assessed, and the provision framework as a Type-2 area.
We guide MSC, NK, and knee review in the order of testing, filing, and physician judgment.
The approach to confirming a cell's source and quality records before treatment.
We guide you through how to proceed with a consultation while confirming records and physician explanation.
We confirm product quality, the positioning as an area where research and commercialization are advancing, the boundary of responsibility, and informed consent, and a physician explains individually.
